Stox
80
Alivus Life Sciences Limited
NSE: ALIVUS · Unclassified
₹1,480.60-1.11%06 Nov 2026
Ask the data
Instant answers about Alivus Life Sciences Limited — computed from its filings, no language modelMarket cap₹18,177 cr
Current price₹1,480.60
High / Low₹1,521 / ₹860
P/E27.1
P/B5.01
Book value₹295.8
ROE18.4%
ROCE24.6%
Debt / equity0.00
Dividend yield0.34%
EPS (TTM)₹54.55
Face value₹2
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Revenue | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 |
| EBITDA | 616 | 642 | 674 | 683 | 797 |
| Operating margin | 29.0% | 29.7% | 29.5% | 28.6% | 31.2% |
| Interest | 28 | 1 | 2 | 2 | 5 |
| Depreciation | 38 | 42 | 53 | 61 | 75 |
| Profit before tax | 565 | 629 | 631 | 654 | 751 |
| Tax | 146 | 162 | 160 | 168 | 187 |
| Net profit | 419 | 467 | 471 | 486 | 564 |
| EPS ₹ | 35.63 | 38.11 | 38.43 | 39.63 | 45.99 |
| Operating cash flow | 598 | 313 | 414 | 392 | 565 |
| Capex | 132 | 170 | 129 | 166 | 307 |
| Dividend paid | 129 | 386 | 276 | 0 | 61 |
| Total assets | — | 2,702 | 2,850 | 3,411 | 3,983 |
| Equity | — | 2,138 | 2,332 | 2,817 | 3,332 |
Quarterly performance
last 22 quarters · ₹ crore| JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 525 | 562 | 522 | 514 | 490 | 509 | 541 | 621 | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 | 682 |
| Operating profit | 160 | 167 | 146 | 142 | 147 | 144 | 145 | 206 | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 | 265 |
| Operating margin | 30.6% | 29.8% | 28.0% | 27.7% | 30.0% | 28.2% | 26.9% | 33.2% | 33.4% | 28.1% | 30.1% | 26.4% | 27.1% | 26.5% | 29.7% | 30.5% | 28.6% | 30.5% | 34.4% | 31.1% | 33.1% | 38.9% |
| Other income | 4 | 2 | 4 | 5 | 9 | 10 | 7 | 3 | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | 14 | 23 | 22 | 20 |
| Interest | 21 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 | 22 |
| Profit before tax | 135 | 153 | 140 | 138 | 146 | 144 | 141 | 198 | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 | 262 |
| Tax | 34 | 37 | 36 | 39 | 38 | 37 | 36 | 51 | 47 | 40 | 42 | 32 | 39 | 32 | 48 | 49 | 41 | 44 | 48 | 53 | 52 | 65 |
| Net profit | 101 | 115 | 104 | 99 | 109 | 107 | 105 | 146 | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 | 197 |
| EPS ₹ | 9.36 | 9.83 | 8.65 | 8.07 | 8.87 | 8.72 | 8.57 | 11.94 | 11.05 | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.57 | 9.91 | 10.60 | 12.25 | 13.23 | 13.04 | 16.02 |
| Revenue YoY | — | — | — | — | -6.7% | -9.3% | 3.5% | 20.9% | 18.1% | 16.9% | 5.9% | -13.6% | 1.8% | -14.9% | 12.1% | 21.0% | 2.2% | 16.0% | 4.8% | 6.1% | 6.4% | 16.0% |
| Profit YoY | — | — | — | — | 7.7% | -7.2% | 1.2% | 48.0% | 24.6% | 11.1% | 13.1% | -33.1% | -17.7% | -19.7% | 15.3% | 44.9% | 9.0% | 36.4% | 9.7% | 14.7% | 31.7% | 51.3% |
Returns & margins
trailing-twelve-month, per quarter| MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | 19.5% | 19.6% | 21.8% | 23.1% | 21.1% | 21.7% | 20.2% | 19.2% | 16.7% | 17.4% | 17.2% | 17.6% | 17.6% | 18.0% | 16.9% | 18.1% | 18.4% |
| ROCE | — | — | 26.5% | 26.6% | 29.4% | 31.1% | 28.5% | 29.3% | 27.1% | 25.8% | 22.4% | 23.4% | 23.3% | 23.8% | 23.8% | 24.3% | 22.7% | 24.2% | 24.6% |
| Net margin | 19.7% | 20.4% | 20.5% | 20.4% | 21.6% | 21.9% | 21.6% | 21.9% | 20.6% | 19.5% | 19.2% | 19.4% | 20.3% | 20.7% | 21.4% | 21.6% | 22.1% | 23.3% | 24.9% |
| EBITDA margin | 29.0% | 28.8% | 28.4% | 28.1% | 29.7% | 30.6% | 30.5% | 31.2% | 29.5% | 27.9% | 27.6% | 27.5% | 28.6% | 29.0% | 29.8% | 31.1% | 31.2% | 32.3% | 34.4% |
| Debt / equity | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest coverage | 21.20 | 77.32 | 1261.60 | 1034.84 | 1143.93 | 821.20 | 630.35 | 534.77 | 408.28 | 400.69 | 395.49 | 393.40 | 272.43 | 202.47 | 167.33 | 137.62 | 140.91 | 148.43 | 164.91 |
| Asset turnover | — | — | 0.76 | 0.77 | 0.80 | 0.83 | 0.79 | 0.80 | 0.80 | 0.80 | 0.71 | 0.74 | 0.70 | 0.70 | 0.68 | 0.69 | 0.64 | 0.65 | 0.62 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | MAR '25 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Share capital | 24 | 24 | 24 | 24 | 25 | 25 | 25 | 25 | 25 |
| Other equity / reserves | 2,118 | 2,114 | 2,367 | 2,308 | 2,514 | 2,793 | 2,991 | 3,308 | 3,607 |
| Total equity | 2,143 | 2,138 | 2,392 | 2,332 | 2,538 | 2,817 | 3,015 | 3,332 | 3,631 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current liabilities | 497 | 504 | 499 | 439 | 464 | 470 | 489 | 508 | 564 |
| Non-current liabilities | 42 | 60 | 62 | 79 | 83 | 124 | 134 | 143 | 147 |
| Total assets | 2,681 | 2,702 | 2,953 | 2,850 | 3,085 | 3,411 | 3,638 | 3,983 | 4,342 |
| Property, plant & equipment | 584 | 775 | 766 | 795 | 804 | 943 | 949 | 1,018 | 1,011 |
| Capital work-in-progress | 191 | 49 | 78 | 101 | 141 | 94 | 173 | 273 | 408 |
| Investments | 0 | 0 | 0 | 0 | 0 | 478 | 634 | 780 | 986 |
| Inventories | 637 | 604 | 670 | 667 | 689 | 674 | 723 | 692 | 783 |
| Receivables | 726 | 807 | 807 | 765 | 775 | 970 | 1,003 | 1,073 | 988 |
| Cash & equivalents | 365 | 284 | 443 | 301 | 446 | 71 | 19 | 2 | 25 |
Cash flow
annual · ₹ crore · line = free cash flow| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | 598 | 313 | 414 | 392 | 565 |
| Cash from investing | -122 | -154 | -116 | -616 | -570 |
| Cash from financing | -79 | -388 | -279 | -6 | -64 |
| Capex | 132 | 170 | 129 | 166 | 307 |
| Free cash flow | 465 | 143 | 285 | 225 | 258 |
| Dividends paid | 129 | 386 | 276 | 0 | 61 |
Where the assets sit
Sep '26 · ₹ croreFixed assets (PPE)₹1,011 cr23%
CWIP₹408 cr9%
Investments₹986 cr23%
Inventories₹783 cr18%
Receivables₹988 cr23%
Cash & equivalents₹25 cr1%
Other assets₹141 cr3%
Peer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Alivus Life Sciences Limited | 18,177 | 1,480.60 | 27.1 | 5.01 | 18.4% |
StoxGud checklist: Bullish setup · 8/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month+8.1%
6 months+32.1%
1 year+63.1%
3Y CAGR+33.8%
5Y CAGR+18.5%
10Y CAGR—
50-day avg₹1,374.34
200-day avg₹1,137.96
RSI (14)72
FAQs
What is the share price of Alivus Life Sciences Limited?
Alivus Life Sciences Limited (ALIVUS) closed at ₹1,480.60 on NSE on 06 Nov 2026.
What is the market cap of Alivus Life Sciences Limited?
₹18,177 crore at the latest close.
What is the P/E ratio of Alivus Life Sciences Limited?
27.1, on trailing-twelve-month earnings from its filings.
How fast is Alivus Life Sciences Limited growing?
Alivus Life Sciences Limited: revenue has compounded at 5.7% a year over three years; net profit at 6.5% a year. Latest-quarter revenue is up 16.0% year on year, profit up 51.3%.
How profitable is Alivus Life Sciences Limited?
On a trailing-twelve-month basis return on equity is 18.4%, return on capital employed 24.6%, operating margin 34.4%, net margin 24.9%.
How much debt does Alivus Life Sciences Limited have?
Alivus Life Sciences Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹25 cr (balance sheet of 2026-09-30). Operating profit covers interest 164.9 times.
Financials parsed from Alivus Life Sciences Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Quarterly from JUN '21, annual from FY22, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.
Alivus Life Sciences Limited · advanced chart